Inventor · disambiguated record
Christian Lavedan
Also filed as: LAVEDAN CHRISTIAN · LAVEDAN CHRISTIAN N · LAVEDAN CHRISTIAN NICOLAS
27 granted patents·25 pending applications·123 citations·filing 1998–2024
96Inventor score
Files withVANDA PHARMACEUTICALS INC32LAVEDAN CHRISTIAN10LAVEDAN CHRISTIAN N2DRESSMAN MARLENE M1IDE SUSAN1
Top patents by PatentIndex Score
52 records- 0197US11667718B2Cancer treatmentVANDA PHARMACEUTICALS INC·Filed 2021·Granted Jun 6, 2023·3 cites·10 claims
- 0296US10653665B2Method of treatmentVANDA PHARMACEUTICALS INC·Filed 2018·Granted May 19, 2020·8 cites·20 claims
- 0395US11266622B2Method of treatmentVANDA PHARMACEUTICALS INC·Filed 2020·Granted Mar 8, 2022·3 cites·7 claims
- 0494US11078289B2Cancer treatmentVANDA PHARMACEUTICALS INC·Filed 2019·Granted Aug 3, 2021·5 cites·9 claims
- 0593US11737993B2Multiple myeloma treatmentVANDA PHARMACEUTICALS INC·Filed 2019·Granted Aug 29, 2023·3 cites·13 claims
- 0693US10179119B2Method of treatmentVANDA PHARMACEUTICALS INC·Filed 2015·Granted Jan 15, 2019·10 cites·10 claims
- 0791US10265282B2Cancer treatmentVANDA PHARMACEUTICALS INC·Filed 2018·Granted Apr 23, 2019·6 cites·10 claims
- 0891US9328387B2Antipsychotic treatment based on SNP genotypeLAVEDAN CHRISTIAN·Filed 2008·Granted May 3, 2016·16 cites·12 claims
- 0990US2024342120A1Multiple myeloma treatmentVANDA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1089US9458507B1Antipsychotic treatment based on SNP genotypeVANDA PHARMACEUTICALS INC·Filed 2016·Granted Oct 4, 2016·7 cites·12 claims
- 1189US9080214B2Genetic markers for efficacy of iloperidone in the treatment of psychotic symptomsLAVEDAN CHRISTIAN·Filed 2008·Granted Jul 14, 2015·8 cites·13 claims
- 1287US11845990B2Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotypeVANDA PHARMACEUTICALS INC·Filed 2021·Granted Dec 19, 2023·1 cites·7 claims
- 1386US2024293355A1Method of treatmentVANDA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1486US2023346719A1Multiple myeloma treatmentVANDA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1585US9074254B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2008·Granted Jul 7, 2015·6 cites·6 claims
- 1685US8652776B2Prediction of QT prolongation based on SNP genotypeLAVEDAN CHRISTIAN·Filed 2008·Granted Feb 18, 2014·12 cites·8 claims
- 1784US9074255B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2010·Granted Jul 7, 2015·6 cites·10 claims
- 1884US9074256B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2010·Granted Jul 7, 2015·6 cites·10 claims
- 1984US9072742B2Method of predicting a predisposition to QT prolongationLAVEDAN CHRISTIAN·Filed 2010·Granted Jul 7, 2015·6 cites·10 claims
- 2081US10563261B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·2 cites·10 claims
- 2179US10570453B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2018·Granted Feb 25, 2020·1 cites·5 claims
- 2279US9057104B2Antipsychotic treatment based on DRD2 or ANKK1 SNP genotypeLAVEDAN CHRISTIAN·Filed 2010·Granted Jun 16, 2015·1 cites·14 claims
- 2378US9408839B2Antipsychotic treatment based on DRD2 or ANKK1 SNP genotypeVANDA PHARMACEUTICALS INC·Filed 2015·Granted Aug 9, 2016·1 cites·14 claims
- 2477US9243295B2Antipsychotic treatment based on DRD2 or ANKK1 SNP genotypeVANDA PHARMACEUTICALS INC·Filed 2015·Granted Jan 26, 2016·1 cites·14 claims
- 2577US2022133681A1Method of treatmentVANDA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2676US10570452B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·1 cites·10 claims
- 2776US10563260B2Method of predicting a predisposition to QT prolongationVANDA PHARMACEUTICALS INC·Filed 2017·Granted Feb 18, 2020·1 cites·10 claims
- 2874US11060144B2Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotypeLAVEDAN CHRISTIAN·Filed 2008·Granted Jul 13, 2021·1 cites·6 claims
- 2970US11458154B2Treatment of CYR61- and VEGF-mediated conditionsVANDA PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2022·0 cites·10 claims
- 3070US2022401464A1Treatment of cyr61- and vegf-mediated conditionsVANDA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3170US2018256521A1Multiple myeloma treatmentVANDA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3265US2016199324A1Multiple myeloma treatmentVANDA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3364US2010063093A1Methods for the administration of iloperidoneWOLFGANG CURT·Filed 2008·Application pending·0 cites
- 3464US2016199323A1Cancer treatmentVANDA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3563US2019360047A1Methods for the administration of iloperidoneVANDA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3660US2014039008A1Methods for the administration of iloperidoneVANDA PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3753US2007141618A1Genes expressed in breast cancer as prognostic and therapeutic targetsDRESSMAN MARLENE M·Filed 2007·Application pending·0 cites
- 3852US8865210B2Stable dosage formulations of imidazolylalkyl-pyridinesLAVEDAN CHRISTIAN N·Filed 2007·Granted Oct 21, 2014·0 cites·12 claims
- 3952US2016053324A1Methods for the administration of iloperidoneVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4052US2011118313A1Identification of a molecular signature for antipsychotics and sermsLAVEDAN CHRISTIAN·Filed 2009·Application pending·0 cites
- 4151US2003064385A1Genes expressed in breast cancer as prognostic and therapeutic targetsFiled 2002·Application pending·0 cites
- 4249US2015259747A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4347US7001720B1Cloning of a gene mutation for parkinson's diseaseUS HEALTH·Filed 1998·Granted Feb 21, 2006·8 cites·6 claims
- 4447US2015225794A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4547US2007155772A1Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory diseaseIDE SUSAN·Filed 2004·Application pending·0 cites
- 4647US2015225795A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4747US2015225793A1Method of predicting a predisposition to qt prolongationVANDA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4845US2008280954A1Method of Improving WakefulnessVANDA PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4944US2005181516A1Bioequivalence determination using expression profilingFiled 2003·Application pending·0 cites
- 5043US2005042614A1Methods to treat diabetes and related conditions based on polymorphisms in the tcf-1 geneFiled 2002·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christian Lavedan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →